Half Year Results 

Vectura boosts earnings on lower R&D costs

Vectura boosts earnings on lower R&D costs

Vectura (VEC) – which specialises in the development of inhaled medicines – has signed 12 manufacturing deals since January. Four of those were recorded during the first half, while the latter were agreed post-period-end – with one such deal announced a day prior to the group’s financial results. The tie-up in question is with Monash University, to develop inhaled oxytocin delivered via an inhaler – preventing post-partum haemorrhage in childbirth. The drug is currently only available via injection, but – according to Vectura – an inhaled alternative could improve ease of use and rapid onset of action.

To continue reading, subscribe today

and enjoy unlimited access to the following:

  • Tips of the Week
  • Funds coverage
  • Weekly features on big investment themes
  • Trading ideas
  • Comprehensive companies coverage
  • Economic analysis
Subscribe
Subscribe to Investors Chronicle

Subscribe today

Full access for just £3.37 a week:

• Tips and recommendations - to beat the market 
• Portfolio clinic & Mr Bearbull - build a well-planned portfolio 
• Expert tools - track and manage investments effortlessly
• Plus free delivery to your home or office

Subscribe Now